Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 190

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer

Open access
Yardley, Denise A., Weaver, Robert, Melisko, Michelle E., Saleh, Mansoor N., Arena, Francis P., Forero, Andres, Cigler, Tessa, Stopeck, Alison, Citrin, Dennis, Oliff, Ira, Bechhold, Rebecca, Loutfi, Randa, Garcia, Agustin A., Cruickshank, Scott, Crowley, Elizabeth, Green, Jennifer, Hawthorne, Thomas, Yellin, Michael J., Davis, Thomas A., Vahdat, Linda T. · 2015 · Journal of Clinical Oncology

Abstract

Purpose: Glycoprotein NMB (gpNMB), a negative prognostic marker, is overexpressed in multiple tumor types. Glembatumumab vedotin is a gpNMB-specific monoclonal antibody conjugated to the potent cytotoxin monomethyl auristatin E. This phase II study investigated the activity of glembatumumab vedotin in advanced breast cancer by gpNMB expression. Patients and Methods: Patients (n = 124) with refractory breast cancer that expressed gpNMB in ≥ 5% of epithelial or stromal cells by central immunohistochemistry were stratified by gpNMB expression (tumor, low stromal intensity, high stromal intensity) and were randomly assigned 2:1 to glembatumumab vedotin (n = 83) or investigator's choice (IC) chemotherapy (n = 41). The study was powered to detect overall objective response rate (ORR) in the glembatumumab vedotin arm between 10% (null) and 22.5% (alternative hypothesis) with preplanned investigation of activity by gpNMB distribution and/or intensity (Stratum 1 to Stratum 3). Results: Glembatumumab vedotin was well tolerated as compared with IC chemotherapy (less hematologic toxicity; more rash, pruritus, neuropathy, and alopecia). ORR was 6% (five of 83) for glembatumumab vedotin versus 7% (three of 41) for IC, without significant intertreatment differences for predefined strata. Secondary end point revealed ORR of 12% (10 of 83) versus 12% (five of 41) overall, and 30% (seven of 23) versus 9% (one of 11) for gpNMB overexpression (≥ 25% of tumor cells). Unplanned analysis showed ORR of 18% (five of 28) versus 0% (0 of 11) in patients with triple-negative breast cancer (TNBC), and 40% (four of 10) versus 0% (zero of six) in gpNMB-overexpressing TNBC. Conclusion: Glembatumumab vedotin is well tolerated in heavily pretreated patients with breast cancer. Although the primary end point in advanced gpNMB-expressing breast cancer was not met for all enrolled patients (median tumor gpNMB expression, 5%), activity may be enhanced in patients with gpNMB-overexpressing tumors and/or TNBC. A pivotal phase II trial (METRIC [Metastatic Triple-Negative Breast Cancer]) is underway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.56.2959

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 190

Metadata

Authors
Yardley, D. A., Weaver, R., Melisko, M. E., Saleh, M. N., Arena, F. P., Forero, A., Cigler, T., Stopeck, A., Citrin, D., Oliff, I., Bechhold, R., Loutfi, R., Garcia, A. A., Cruickshank, S., Crowley, E., Green, J., Hawthorne, T., Yellin, M. J., Davis, T. A., & Vahdat, L. T.
Venue
Journal of Clinical Oncology
Published
2015-05-10
Volume
33
Issue
14
Pages
1609-1619
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2118102300
Cited by
190
References
1
FWCI
5.79
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer. https://app.cochat.ai/papers/10.1200/jco.2014.56.2959
The paper
Yardley, D. A., Weaver, R., Melisko, M. E., Saleh, M. N., Arena, F. P., Forero, A., Cigler, T., Stopeck, A., Citrin, D., Oliff, I., Bechhold, R., Loutfi, R., Garcia, A. A., Cruickshank, S., Crowley, E., Green, J., Hawthorne, T., Yellin, M. J., Davis, T. A., & Vahdat, L. T. (2015). EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.56.2959

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.